News stories about MiMedx Group (NASDAQ:MDXG) have trended positive on Friday, AlphaOne Sentiment reports. The research firm, a unit of Accern, identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MiMedx Group earned a media sentiment score of 0.39 on AlphaOne’s scale. AlphaOne also assigned headlines about the medical equipment provider an impact score of 83 out of 100, meaning that recent media coverage is very likely to have an effect on the company’s share price in the immediate future.

Several equities research analysts have recently issued reports on MDXG shares. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective (up previously from $12.00) on shares of MiMedx Group in a research note on Thursday, April 13th. TheStreet upgraded shares of MiMedx Group from a “c+” rating to a “b” rating in a research note on Thursday, March 16th. Zacks Investment Research raised MiMedx Group from a “sell” rating to a “hold” rating in a research report on Tuesday, February 21st. Finally, Piper Jaffray Companies initiated coverage on MiMedx Group in a research report on Friday, March 3rd. They issued an “overweight” rating and a $10.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. MiMedx Group has a consensus rating of “Buy” and a consensus target price of $12.33.

MiMedx Group (NASDAQ:MDXG) traded down 0.1232% on Friday, hitting $14.4322. The company had a trading volume of 113,675 shares. The firm has a 50-day moving average price of $12.03 and a 200-day moving average price of $9.56. MiMedx Group has a 12-month low of $6.90 and a 12-month high of $15.40. The firm has a market capitalization of $1.52 billion, a PE ratio of 103.0871 and a beta of 0.97.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Friday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. MiMedx Group had a return on equity of 18.18% and a net margin of 8.75%. The business had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $72.60 million. During the same period in the previous year, the business earned $0.04 earnings per share. The firm’s revenue was up 36.1% on a year-over-year basis. On average, equities research analysts anticipate that MiMedx Group will post $0.30 earnings per share for the current fiscal year.

In related news, insider William Charles Taylor sold 26,000 shares of the business’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $11.40, for a total transaction of $296,400.00. Following the completion of the transaction, the insider now directly owns 540,460 shares in the company, valued at $6,161,244. The transaction was disclosed in a document filed with the SEC, which is available through this link. 12.30% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

About MiMedx Group

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

5 Day Chart for NASDAQ:MDXG

Receive News & Stock Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related stocks with our FREE daily email newsletter.